SteadyMed (STDY) Stock Price, News & Analysis

Company Overview

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.

Key Stats

• Today's Range: $4.73 to $4.73
• 50-Day Range: N/A
• 52-Week Range: $2.60 to $6.45
• Volume: 160 shs
• Average Volume: 85,138 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

STDY Stock Analysis - Frequently Asked Questions

How were SteadyMed's earnings last quarter?

SteadyMed Ltd. (NASDAQ:STDY) announced its earnings results on Tuesday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.17.

When did SteadyMed IPO?

SteadyMed (STDY) raised $56 million in an initial public offering on Friday, March 20th 2015. The company issued 4,300,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What other stocks do shareholders of SteadyMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SteadyMed investors own include Amicus Therapeutics (FOLD), Protalix BioTherapeutics (PLX), Fate Therapeutics (FATE), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Rigel Pharmaceuticals (RIGL) and Sophiris Bio (SPHS).

Company Calendar

• Last Earnings: 8/14/2018
• Today: 9/16/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:STDY
• CIK: 1619087
• Web: www.steadymed.com
• Phone: 925-272-4999
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A